Earnings Feed
Start Free
Home/Filings/4/0000914190-14-000016
4//SEC Filing

Arno Therapeutics, Inc 4

Accession 0000914190-14-000016

CIK 0001195116operating
View on SEC.govCompany Profile

Filed

Jan 27, 7:00 PM ET

Accepted

Jan 28, 4:25 PM ET

Size

18.3 KB

Accession

0000914190-14-000016

Insider Transaction Report

Form 4
Period: 2014-01-24
Arno Therapeutics, IncARNI
Proniuk Stefan
VP of Product Development
Transactions
  • Award

    Stock Option (right to buy)

    2014-01-24+171,877→ 171,877 total
    Exercise: $2.90Exp: 2024-01-24→ Common Stock (171,877 underlying)
Holdings

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-01-14→ Common Stock (6,875 underlying)
    6,875

  • 2012 Series A Warrants (right to buy)

    Exercise: $2.40From: 2012-11-26Exp: 2017-11-26→ Common Stock (13,888 underlying)
    13,888

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-11-04→ Common Stock (45,701 underlying)
    45,701

  • 2012 Series B Warrants (right to buy)

    Exercise: $2.40From: 2013-10-29Exp: 2014-10-31→ Common Stock (8,333 underlying)
    8,333

  • Common Stock

    10,047

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-06-20→ Common Stock (17,187 underlying)
    17,187

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-09-19→ Common Stock (10,000 underlying)
    10,000

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-01-14→ Common Stock (2,291 underlying)
    2,291

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-06-20→ Common Stock (7,191 underlying)
    7,191
Footnotes (7)
  • [F1]25% vested on 6/22/12 and thereafter in 24 equal monthy installments.
  • [F2]On 6/22/2011, the Reporting Person was granted an option to purchase up to 112,500 shares of common stock of the Issuer. Up to 1/3 of the shares subject to the option may vest annually (or a pro rata portion thereof for a period of less than a full year) based on the achievement of certain performance milestones as determined by the Board of Directors (the 'Board') of the Issuer. On 1/17/2012, the Board determined that options for the prorated period ending 12/31/2011 would vest in the maximum potential amount of 20,034 shares. On 1/14/2013, the Board determined that options for the period ending 12/31/2012 would vest in the maximum potential amount of 37,500 shares.
  • [F3]50% vested on 9/19/11 and thereafter in 24 equal monthly installments.
  • [F4]1/3 vested on 1/14/13 and thereafter will vest in 24 equal monthy installments, commencing 1/31/13.
  • [F5]On 1/14/2013, the Reporting Person was granted an option to purchase up to 55,000 shares of common stock of the Issuer. 1/3 of the shares subject to the option were immediately vested and up to 1/2 of the remaining shares subject to the option may vest annually, based on the achievement of certain performance milestones as determined by the Board.
  • [F6]Vests in equal 36-monthly installments commencing 12/4/13.
  • [F7]Vests 25% on first anniversary date and thereafter will vest in 24 equal monthly installments.

Documents

1 file

Issuer

Arno Therapeutics, Inc

CIK 0001195116

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001195116

Filing Metadata

Form type
4
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 4:25 PM ET
Size
18.3 KB
View on SEC.gov